# EDGAR Filing Document

**Accession Number:** 0002029039
**File Stem:** 0001493152-26-009621
**Filing Date:** 2026-3
**Character Count:** 1941
**Document Hash:** 6588f1e97a6aaf9b6983ce55ce921ce7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-009621.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001493152-26-009621

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260311

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nasus Pharma Ltd
- **CENTRAL INDEX KEY:** 0002029039
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 516022712
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003
- **BUSINESS PHONE:** 972 54-255-3956

**MAIL ADDRESS:**
- **STREET 1:** 29 HARAKEVET ST
- **CITY:** TEL AVIV - YAFO
- **STATE:** L3
- **ZIP:** 6618003

**Nasus Pharma Ltd.**

**P.O. Box 284**

**Tel Aviv, Israel 6100201**

March 11, 2026

*<u>VIA EDGAR</u>*

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: Nasus Pharma Ltd. (CIK 0002029039) <br> <u>Registration Statement No. 333-293950 on Form F-1 (the "Registration Statement")</u> 

Ladies and Gentlemen:

Nasus Pharma Ltd. (the "<u>Registrant</u>") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it may become effective on March 13, 2026, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant respectfully requests that it be notified of such effectiveness by an e-mail or phone call to Eric Victorson, Esq. of Sullivan & Worcester LLP at evictorson@sullivanlaw.com or (212) 660-3092.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Nasus Pharma Ltd. | Nasus Pharma Ltd. |
| By: | */s/ Dan Teleman* |
|  | Dan Teleman<br> Chief Executive Officer |

---